Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WGVKF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
FS-1502
|
|||||
| Synonyms |
FS-1502; Herceptin-LC-LBG-MMAF; IKS 014; IKS-014; IKS014; LCB14; LCB14-0110; Trastuzumab-LC-LBG-MMAF
Click to Show/Hide
|
|||||
| Organization |
Iksuda Therapeutics; Shanghai Fosun Pharmaceutical
|
|||||
| Drug Status |
Phase 3
|
|||||
| Indication |
In total 2 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin F
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
| Combination Type |
mafodotin
|
|||||
